#ESMO26 | NATALEE: 6-year outcomes

Adjuvant ribociclib + NSAI vs NSAI alone in eligible HR+/HER2− stage II–III EBC:

▪️ OS
HR 0.809 (95% CI 0.661–0.989)
Absolute 6-year benefit: 2.1 percentage points

▪️ IDFS
HR 0.741 (95% CI 0.646–0.849)
Absolute 6-year benefit: 5.3 percentage points

Benefit persists with patients off ribociclib for a median of ~3 years.

𝘔𝘺 𝘬𝘦𝘺 𝘲𝘶𝘦𝘴𝘵𝘪𝘰𝘯:
𝘐𝘯 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭𝘭𝘺 𝘦𝘭𝘪𝘨𝘪𝘣𝘭𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘭𝘰𝘸 𝘖𝘯𝘤𝘰𝘵𝘺𝘱𝘦 𝘋𝘟 𝘙𝘚 𝘢𝘯𝘥/𝘰𝘳 𝘭𝘰𝘸 𝘰𝘷𝘦𝘳𝘢𝘭𝘭 𝘳𝘦𝘤𝘶𝘳𝘳𝘦𝘯𝘤𝘦 𝘳𝘪𝘴𝘬, 𝘦𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘭𝘺 𝘕0 𝘥𝘪𝘴𝘦𝘢𝘴𝘦, 𝘪𝘴 𝘵𝘩𝘦 𝘢𝘣𝘴𝘰𝘭𝘶𝘵𝘦 𝘣𝘦𝘯𝘦𝘧𝘪𝘵 𝘭𝘢𝘳𝘨𝘦 𝘦𝘯𝘰𝘶𝘨𝘩 𝘵𝘰 𝘫𝘶𝘴𝘵𝘪𝘧𝘺 3 𝘺𝘦𝘢𝘳𝘴 𝘰𝘧 𝘳𝘪𝘣𝘰𝘤𝘪𝘤𝘭𝘪𝘣, 𝘤𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘪𝘯𝘨 𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺, 𝘮𝘰𝘯𝘪𝘵𝘰𝘳𝘪𝘯𝘨 𝘣𝘶𝘳𝘥𝘦𝘯, 𝘢𝘯𝘥 𝘘𝘖𝘓?

#BreastCancer #NATALEE